(MedPage Today) — BARCELONA — A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic lupus erythematosus (SLE) get symptoms under control, according to phase III trial data…
Source link : https://www.medpagetoday.com/meetingcoverage/eular/116036
Author :
Publish date : 2025-06-12 16:13:00
Copyright for syndicated content belongs to the linked Source.
